A Phase 3 interventional study of Verteporfin Photodynamic Therapy and Ranibizumab in Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis. Completed at 43 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing verteporfin in Macular Degeneration — none open to participants now, none under way, none of them phase 3. Verteporfin · Macular Degeneration.
Among the 18 studies testing verteporfin in Macular Degeneration, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2007, is one of 4 in phase 3, and was the 9th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →None of the 18 studies testing verteporfin in Macular Degeneration is open now. The open studies under Macular Degeneration, anywhere →
Verteporfin: first FDA approval 2000 (VISUDYNE), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 5 · Phase 4 6
First in 2002; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 321 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 60 across the 17 interventional studies. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 18 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 13th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2007, is one of 23 in phase 3, and was the 9th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing verteporfin in Macular Degeneration, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
Drug: Verteporfin Photodynamic Therapy · Drug: Ranibizumab · Drug: Ranibizumab Placebo
Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).
Drug: Ranibizumab · Drug: Verteporfin Placebo
Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
Drug: Verteporfin Photodynamic Therapy · Drug: Ranibizumab · Drug: Ranibizumab Placebo
After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
Also known as: Visudyne
Ranibizumab 0.5 mg administered as an intravitreal injection.
Also known as: Lucentis
To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.
Time frame: Baseline and Month 12
Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.
Time frame: Month 2 up to Month 11
Change From Baseline in Total Area of Leakage of the Study Eye at Month 12
Total area of leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).
Time frame: Baseline and Month 12
Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12
The percentage of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).
Time frame: Month 12
Change From Baseline in Central Retinal Thickness at Month 12
Optical coherence tomography was performed in the study eyes and the evaluations of the images were performed by the central reading center.
Time frame: Baseline and Month 12
| Milestone | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy |
|---|---|---|---|
| Started | 104 | 105 | 112 |
| Completed | 91 | 93 | 102 |
| Not completed | 13 | 12 | 10 |
| Withdrew: Adverse event | 4 | 3 | 4 |
| Withdrew: Death | 3 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 6 | 3 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.
| Letters | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy |
|---|---|---|---|
| Baseline | 53.7 ± 13.52 | 54.6 ± 12.78 | 54.8 ± 13.55 |
| Month 12 | 59.0 ± 17.47 | 59.0 ± 18.03 | 63.0 ± 18.88 |
| Change from baseline | 5.3 ± 15.66 | 4.4 ± 15.47 | 8.1 ± 15.09 |
Total area of leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).
| mm^2 | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy |
|---|---|---|---|
| Baseline | 6.654 ± 4.0956 | 6.211 ± 5.0618 | 6.931 ± 4.6473 |
| Month 12 | 3.472 ± 4.2340 | 3.024 ± 4.0188 | 3.177 ± 4.9930 |
| Change from Baseline | -3.182 ± 4.9729 | -3.187 ± 5.9744 | -3.753 ± 5.8005 |
The percentage of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).
| Percentage of participants | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy |
|---|---|---|---|
| Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12 | 58.2 ± 0 | 54.5 ± 0 | 41.8 ± 0 |
Optical coherence tomography was performed in the study eyes and the evaluations of the images were performed by the central reading center.
| micrometer | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy |
|---|---|---|---|
| Baseline | 444.654 ± 137.7119 | 446.638 ± 129.5482 | 456.824 ± 153.4270 |
| Month 12 | 292.921 ± 79.2733 | 305.719 ± 80.4508 | 284.586 ± 75.4892 |
| Change from Baseline | -151.733 ± 135.6200 | -140.919 ± 128.0741 | -172.238 ± 166.6691 |
The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.
| Percent of participants | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab |
|---|---|---|
| Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit | 92.6 (85.4 to 97.0) | 83.5 (74.6 to 90.3) |
Collected over Cumulative up to Month 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Verteporfin SF + Ranibizumab | — | 32/104 (30.8%) | 85/104 (81.7%) |
| Verteporfin RF + Ranibizumab | — | 29/106 (27.4%) | 81/106 (76.4%) |
| Ranibizumab Monotherapy | — | 41/111 (36.9%) | 87/111 (78.4%) |
| Event | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 2/104 | 2/106 | 6/111 |
| Visual acuity reduced (Study eye)Eye disorders | 4/104 | 1/106 | 3/111 |
| PneumoniaInfections and infestations | 2/104 | 3/106 | 4/111 |
| BradycardiaCardiac disorders | 0/104 | 0/106 | 3/111 |
| Transient ischaemic attackNervous system disorders | 0/104 | 1/106 | 3/111 |
| Atrial fibrillationCardiac disorders | 2/104 | 0/106 | 1/111 |
| AstheniaGeneral disorders | 2/104 | 0/106 | 0/111 |
| Hip fractureInjury, poisoning and procedural complications | 2/104 | 1/106 | 1/111 |
| Myocardial infarctionCardiac disorders | 1/104 | 2/106 | 1/111 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/104 | 2/106 | 1/111 |
| Event | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy |
|---|---|---|---|
| Eye pain (Study eye)Eye disorders | 22/104 | 14/106 | 14/111 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 13/104 | 18/106 | 18/111 |
| HypertensionVascular disorders | 9/104 | 13/106 | 12/111 |
| NasopharyngitisInfections and infestations | 10/104 | 6/106 | 13/111 |
| Choroidal neovascularisation (Fellow eye)Eye disorders | 7/104 | 12/106 | 8/111 |
| Macular degeneration (Fellow eye)Eye disorders | 8/104 | 6/106 | 12/111 |
| Upper respiratory tract infectionInfections and infestations | 11/104 | 10/106 | 7/111 |
| Myodesopsia (Study eye)Eye disorders | 2/104 | 11/106 | 10/111 |
| Visual acuity reduced (Study eye)Eye disorders | 10/104 | 9/106 | 5/111 |
| Lacrimation increased (Study eye)Eye disorders | 6/104 | 6/106 | 10/111 |
| Age Continuous(years) | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy | Total |
|---|---|---|---|---|
| Mean | 77.5 ± 8.42 | 77.4 ± 8.48 | 77.2 ± 7.97 | 77.3 ± 8.26 |
| Sex: Female, Male(Participants) | Verteporfin SF + Ranibizumab | Verteporfin RF + Ranibizumab | Ranibizumab Monotherapy | Total |
|---|---|---|---|---|
| Female | 64 | 53 | 75 | 192 |
| Male | 40 | 52 | 37 | 129 |
The record gives a start of Feb 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verteporfin